Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise

With a supply hitch expected to blow over soon, Novo Nordisk has high hopes for newly minted obesity med Wegovy. In fact, the company has more than doubled its previous 2025 sales target for the fast-growing franchise.

Novo Nordisk is gunning for more than 25 billion Danish krone ($3.72 billion) in obesity sales by 2025, the company said Thursday. Novo had previously aimed (PDF) to generate around 11.35 billion Danish krone (roughly $1.69 billion) by the middle of the decade, based on earlier weight loss med Saxenda’s 2019 sales of 5.7 billion Danish krone ($849 million).